CAR T Cell Therapy Market Size, Trends, Growth, Industry Analysis and Forecast 2025

The global CAR T cell therapy market is estimated to grow at a CAGR of nearly 48% during the forecast period. The major factors contributing to the growth of the market include a significant prevalence of cancer across the globe and rising FDA approvals for cell and gene therapy. As per the World Health Organization (WHO), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. There were 43.8 million persons living with cancer in 2018 who were diagnosed within the last 5 years. This rising prevalence of cancer is attributing to the development of CAR T cell therapy. It is a form of immunotherapy that utilizes specially altered T cells, a part of the immune system to attack cancer.

Get Sample Copy of CAR T Cell Therapy Market at: https://www.omrglobal.com/request-sample/car-t-cell-therapy-market

The major players operating in the market include Novartis International AG, Gilead Sciences, Inc., Pfizer, Inc., Bristol-Myers Squibb Co., and Takeda Pharmaceutical Co. Ltd.

There are currently two CAR T cell therapies approved for the treatment of cancer, which includes Yescarta and Kymriah. Yescarta was approved by the US FDA in October 2017, for the treatment of diffuse large B-cell lymphoma (DLBCL). Kymriah was approved by the US FDA in May 2018, for the treatment of adults with certain kinds of non-Hodgkin lymphoma. Kymriah is also approved for the treatment of children and young adults with leukemia. In clinical trials, more than 80% of young adults and children treated with Kymriah achieved cancer remission.

A full report of Global CAR T Cell Therapy Market is available at: https://www.omrglobal.com/industry-reports/car-t-cell-therapy-market

Early results of CAR T-cell therapy to treat lymphoma and other blood cancers are promising. Multiple patients with failed standard treatments or whose blood cancers returned achieved complete success with CAR T cell therapy. As a result, the US FDA is focusing on the approvals of cell and gene therapies. Several CAR T cell therapies are in clinical phases for the treatment of breast cancer, colorectal cancer and blood cancer. The launch of these novel therapies will likely offer an opportunity for the growth of the market.

Market Segmentation

Global CAR T Cell Therapy Market by Application

o Non-Hodgkin Lymphoma
o Acute Lymphocytic Leukemia
o Others (Multiple Myeloma, Hodgkin Lymphoma, and Breast Cancer)

Global CAR T Cell Therapy Market by Target Antigen

o CD19
o CD22
o Others (CD123, CD33, and BCMA)

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/car-t-cell-therapy-market

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 7803040404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

This release was published on openPR.